Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 31,348 Shares of Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 31,348 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1.45, for a total value of $45,454.60. Following the sale, the chairman now owns 1,260,195 shares in the company, valued at $1,827,282.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Neil Desai also recently made the following trade(s):

• On Wednesday, May 1st, Neil Desai sold 40,000 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.93, for a total value of $77,200.00.

Aadi Bioscience Trading Down 7.0 %

AADI stock opened at $1.32 on Wednesday. Aadi Bioscience, Inc. has a 12-month low of $1.28 and a 12-month high of $7.24. The stock has a market cap of $32.41 million, a price-to-earnings ratio of -0.52 and a beta of 0.69. The business’s 50-day moving average is $1.78 and its 200 day moving average is $1.90.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.02). Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. The firm had revenue of $5.35 million during the quarter, compared to analyst estimates of $6.41 million. As a group, equities analysts forecast that Aadi Bioscience, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Aadi Bioscience

A hedge fund recently bought a new stake in Aadi Bioscience stock. Marquette Asset Management LLC acquired a new position in Aadi Bioscience, Inc. (NASDAQ:AADI) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 57,807 shares of the company’s stock, valued at approximately $135,000. Marquette Asset Management LLC owned about 0.24% of Aadi Bioscience at the end of the most recent quarter. Institutional investors and hedge funds own 52.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Aadi Bioscience in a research report on Tuesday, May 14th.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.